Atlas Trials

Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma

Clinical trial NCT02938728 · UNKNOWN

Trial details

NCT number
NCT02938728
Sponsor
Assistance Publique - Hôpitaux de Paris
Status
UNKNOWN
Study type
OBSERVATIONAL
Malignant Melanoma
Start date
2016-11-01
Primary completion
2020-03-01
Enrollment
120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.